CN101690727B - 治疗关节炎的药物及其制备方法 - Google Patents
治疗关节炎的药物及其制备方法 Download PDFInfo
- Publication number
- CN101690727B CN101690727B CN2009101878027A CN200910187802A CN101690727B CN 101690727 B CN101690727 B CN 101690727B CN 2009101878027 A CN2009101878027 A CN 2009101878027A CN 200910187802 A CN200910187802 A CN 200910187802A CN 101690727 B CN101690727 B CN 101690727B
- Authority
- CN
- China
- Prior art keywords
- group
- hyaluronic acid
- medicine
- glucosamine sulfate
- property
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 206010003246 arthritis Diseases 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims abstract description 84
- 229960002849 glucosamine sulfate Drugs 0.000 claims abstract description 82
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 73
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 72
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 72
- 239000000203 mixture Substances 0.000 claims description 63
- 239000002775 capsule Substances 0.000 claims description 39
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 238000009472 formulation Methods 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 230000002917 arthritic effect Effects 0.000 claims description 15
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 10
- 229920002774 Maltodextrin Polymers 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 10
- 229940035034 maltodextrin Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract description 8
- 229960002442 glucosamine Drugs 0.000 abstract description 8
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 57
- 239000000243 solution Substances 0.000 description 45
- 230000000694 effects Effects 0.000 description 37
- 108090001005 Interleukin-6 Proteins 0.000 description 36
- 108010002352 Interleukin-1 Proteins 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 210000000629 knee joint Anatomy 0.000 description 17
- 238000007789 sealing Methods 0.000 description 17
- 238000010171 animal model Methods 0.000 description 16
- 201000008482 osteoarthritis Diseases 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001179 synovial fluid Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- XKGUZGHMWUIYDR-UHFFFAOYSA-N benzyl n-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical compound C=1C=C(N2CCOCC2)C(F)=CC=1NC(=O)OCC1=CC=CC=C1 XKGUZGHMWUIYDR-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 150000004263 amino monosaccharides Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000426 patellar ligament Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组名称 | 血清IL-6含量(单位Pg/ml) |
A | 53.3±9.2 |
B1 | 78.6±12.1 |
B2 | 101.2±14.6 |
C1 | 79.4±15.6 |
C2 | 85.7±6.3 |
C3 | 68.4±6.9 |
C4 | 75.9±6.4 |
C5 | 88.3±9.8 |
C6 | 79.8±12.3 |
D | 158.6±17.2 |
组名称 | 关节液IL-1含量(单位pg/ml) |
A | 6.82±0.44 |
B1 | 10.21±0.21 |
B2 | 14.24±0.32 |
C1 | 8.02.±0.25 |
C2 | 10.47±0.31 |
C3 | 12.41±0.84 |
D | 18.6±0.47 |
组名称 | 膝关节活动度 |
A | 147.4±4,5 |
B1 | 108.2±9.3 |
B2 | 85.3±8.2 |
C1 | 114.5±11.1 |
C2 | 112.2±8.3 |
C3 | 96.8±7.5 |
D | 39.2±12.3 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101878027A CN101690727B (zh) | 2009-10-12 | 2009-10-12 | 治疗关节炎的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101878027A CN101690727B (zh) | 2009-10-12 | 2009-10-12 | 治疗关节炎的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101690727A CN101690727A (zh) | 2010-04-07 |
CN101690727B true CN101690727B (zh) | 2011-10-12 |
Family
ID=42079477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101878027A Expired - Fee Related CN101690727B (zh) | 2009-10-12 | 2009-10-12 | 治疗关节炎的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101690727B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3160440B1 (fr) * | 2014-06-30 | 2021-10-27 | NUTRICOS Technologies | Produits de combinaison et compositions cosmétiques pour lutter contre les désordres de la peau et son vieillissement affectant les kératinocytes et/ou les fibroblastes et le derme |
-
2009
- 2009-10-12 CN CN2009101878027A patent/CN101690727B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101690727A (zh) | 2010-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2701787T3 (es) | Combinaciones de ácido hialurónico y una vitamina para inhibir inflamación | |
Hanson et al. | Oral treatment with a glucosamine-chondroitin sulfate compound for degenerative joint disease in horses: 25 cases | |
US20180311272A1 (en) | Compositions and Methods for Treating Joints | |
CN101658490A (zh) | 西林瓶包装的甲磺酸罗哌卡因注射液的制备方法 | |
CN102949710B (zh) | 增加骨密度的药物组合物或保健品及其制备方法 | |
CN1859918B (zh) | 透明质酸在制备治疗急性和过劳扭伤、拉伤的药物中的应用 | |
CN103735572A (zh) | 一种具有增加骨密度、抗炎镇痛作用的组合物及其制备方法 | |
CN105796589A (zh) | 用于治疗关节的组合物和方法 | |
CN101721422B (zh) | 治疗关节炎的药物及其制备方法 | |
CN101690727B (zh) | 治疗关节炎的药物及其制备方法 | |
CN102441023B (zh) | 一种治疗骨科疾病的注射用组合物 | |
CN101455396A (zh) | 一种促进骨和骨关节健康的营养保健食品 | |
CN106905444B (zh) | 淫羊藿苷与透明质酸的结合物及其制备方法和应用 | |
RU2367447C1 (ru) | Способ лечения ранних стадий остеоартроза коленного сустава | |
CN104824511A (zh) | 一种益生元组合物 | |
CN115869293A (zh) | 莱菔素用于制备治疗类风湿性关节炎的药物的用途 | |
CN105982911A (zh) | 一种氨基葡萄糖和玻璃酸钠组合的高粘弹性注射液的制备方法 | |
CN107840897A (zh) | 一种用于治疗骨关节炎的透明质酸镁盐及其制备方法和应用 | |
CN105267949A (zh) | 退行性关节炎暨骨质疏松症的药物组方及其片剂制备方法 | |
Brailsford | Some radiographic manifestations of early scurvy | |
KR101784673B1 (ko) | 관절염의 예방 또는 치료용 약학적 조성물 | |
CN103040911A (zh) | 一种治疗骨科疾病的注射用组合物 | |
CN1240389C (zh) | 磺酰化乙酰氨基葡萄糖药物组合物及其应用 | |
CN101244137B (zh) | 一种治疗肺炎及高热、低热不退的药物及其配制方法 | |
CN110038027A (zh) | 用于抑制发炎的医药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SUN QI ZHOU MIN Owner name: SHENYANG USCAL BIOMED. CO., LTD. Free format text: FORMER OWNER: CHENG PENG Effective date: 20110919 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110000 SHENYANG, LIAONING PROVINCE TO: 110179 SHENYANG, LIAONING PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110919 Address after: 110179 Shenyang Hunnan New Long Street No. 111 room 10-1 Applicant after: Shenyang USCAL Biomed. Co., Ltd. Address before: 110000 Liaoning, Shenyang, Tiexi Jin Industrial Street, No. 7 4-5-1 Applicant before: Cheng Peng Co-applicant before: Sun Qi Co-applicant before: Zhou Min |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111012 Termination date: 20151012 |
|
EXPY | Termination of patent right or utility model |